Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
Hanneke C. Kluin‐Nelemans, Mohamad Jawhar, Andreas Reiter, Björn van Anrooij, Jason Gotlib, Karin Hartmann, Anja Illerhaus, Hanneke N.G. Oude Elberink, Aleksandra Górska, Marek Niedoszytko, Magdalena Lange, Luigi Scaffidi, Roberta Zanotti, Patrizia Bonadonna, Cecelia Perkins, Chiara Elena, Luca Malcovati, Khalid Shoumariyeh, Nikolas von Bubnoff, Sabine Müller, Massimo Triggiani, Roberta Parente, Juliana Schwaab, Michael Kundi, Anna Belloni Fortina, Francesca Caroppo, Knut Brockow, Alexander Zink, David Fuchs, Irena Angelova‐Fischer, Akif Selim Yavuz, Michael Doubek, Mattias Mattsson, Hans Hägglund, Jens Panse, Anne Simonowski, Vito Sabato, Tanja Schug, Madlen Jentzsch, Christine Breynaert, Judit Várkonyi, Vanessa E. Kennedy, Olivier Hermine, Julien Rossignol, Michel Arock, Peter Valent, Wolfgang R. Sperr
Abstract
Male sex has a major impact on clinical features, disease progression, and survival in mastocytosis. Male patients have an inferior survival, which seems related to the fact that they more frequently develop a multi-mutated AdvSM associated with a high-risk molecular background.